CompletedPhase 2NCT04251182
Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects
Studying Early-onset autosomal dominant Alzheimer disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- T3D Therapeutics, Inc.
- Principal Investigator
- Blake Swearingen, MST3D Therapeutics, Inc.
- Intervention
- 15mg T3D-959(drug)
- Enrollment
- 250 enrolled
- Eligibility
- 50-90 years · All sexes
- Timeline
- 2021 – 2023
Study locations (1)
- T3D Therapeutics, Durham, North Carolina, United States
Collaborators
National Institute on Aging (NIA) · Clinilabs, Inc. · Alzheimer's Association
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04251182 on ClinicalTrials.govOther trials for Early-onset autosomal dominant Alzheimer disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT05643144Enhancing Shared Decision-making to Guide Care for People With Dementia and DiabetesIndiana University
- RECRUITINGNANCT07294885Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's DiseaseGeneral Hospital of Shenyang Military Region
- RECRUITINGNANCT07532590Patients With Pancreatic Tumor: Use of an App to Monitor Progress in a Simple and Intuitive Way by Periodically Completing Targeted Questionnaires and Providing Educational and Informational Content.Casa di Cura Dott. Pederzoli
- ENROLLING BY INVITATIONNCT07314190Retrospective Observational Study of Blood-based Biomarkers in the Diagnosis and Monitoring of Patients With a Neurodegenerative Disease or Mental DisorderFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- ENROLLING BY INVITATIONNANCT07425106Comparative Study of High Performance Low-Cost Optical Coherence Tomography (Stage 1B, 2 and 3)Duke University
- RECRUITINGPHASE1NCT07328451A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's DiseaseDenali Therapeutics Inc.
- RECRUITINGPHASE1NCT07234942A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)Hoffmann-La Roche
- RECRUITINGNCT07207642Sweet Night (Musical Diffusion by Caregivers ): Effects of Musical Diffusion by Caregivers on Sleep Onset and Behavioral Regulation in a Protected LivingCentre Hospitalier Universitaire de Saint Etienne
See all trials for Early-onset autosomal dominant Alzheimer disease →